Aids commentary azidothymidine

Journal of Infectious Diseases

Volumn 157, Issue 3, 1988, Pages 427-431

  Hirsch, Martin S ^a,a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ZIDOVUDINE; DRUG DERIVATIVE; THYMIDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG ACTIVITY; DRUG EFFICACY; DRUG INTERACTION; DRUG TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; PHARMACOKINETICS; SIDE EFFECT; ADULT; AIDS RELATED COMPLEX; CLINICAL TRIAL; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED COMPLEX; CLINICAL TRIALS; HUMAN; THYMIDINE; ZIDOVUDINE;

EID: 0023976265     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/157.3.427     Document Type: Article

References (28)

1. Horwitz JP, Chua J, Noel M. Nucleosides. V. The monomesy lates of l-(2’-deoxy-β-D-lyxofuranosyl)thymine. J Organ Chem 1964;29:2076-8.
2. Ostertag W, Roesler G, Kreig CJ, Kind J, Cole T, Crozier T, Gaedicke G, Steinheider G, Kluge N, Dube S. Induction of endogenous virus and of thymidine kinase by bromodeoxyuridine in cell cultures transformed by Friend virus. Proc Natl Acad Sci USA 1974;71:4980-5.
3. Mitsuya H, Weinhold KJ, Furman PA, St. Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S. 3’-Azido-3’-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985;82:7096-7100.
4. Sommadossi J-P, Carlisle R. Toxicity of 3’-azido-3’-deoxy-thymidine and 9-(l,3-dihydroxy-2-propoxymethyl)-guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother 1987;31:452-4.
5. Richman DD, Kornbluth RS, Carson DA. Failure of dideoxynucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages. J Exp Med 1987;166:1144-9.
6. Elwell LP, Ferone R, Freeman GA, Fyfe JA, Hill JA, Ray PH, Richards CA, Singer SC, Knick VB, Rideout JL, Zimmerman TP. Antibacterial activity and mechanism of action of 3’-azido-3’-deoxythymidine (BW A509U). Antimicrob Agents Chemother 1987;31:274-80.
7. Furman PA, Fyfe JA, St. Clair MH, Weinhold K, Rideout JL, Freeman GA, Nusinoff Lehrman S, Bolognesi DP, Broder S, Mitsuya H, Barry DW. Phosphorylation of 3’-azido-3’-deoxythymidine and selective interaction of the 5’-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986;83:8333-7.
8. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, King D, the AZT Collaborative Working Group. The efficacy of azidothymi-dine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:185-91.
9. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS, Jackson GG, Durack DT, Nusinoff-Lehrman S, the AZT Collaborative Working Group. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:192-7.
10. Yarchoan R, Klecker RW, Weinhold KJ, Markham PD, Lyerly HK, Durack DT, Gelmann E, Nusinoff Lehrman S, Blum RM, Barry DW, Shearer GM, Fischl MA, Mitsuya H, Gallo RC, Collins JM, Bolognesi DP, Myers CE, Broder S. Administration of 3’-azido-3’-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986;1:575-80.
11. Fischl MA, Reese J, Dearmas L, Dickinson G, Parks W. Long term experience with zidovudine (AZT) in patients with AIDS and AIDS-related complex [abstract no. 386], In: Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1987.
12. Chaisson RE, Allain J-P, Leuther M, Volberding PA. Significant changes in HIV antigen level in the serum of patients treated with azidothymidine. N Engl J Med 1986; 315:1610-1.
13. Wong RJ, Jacobson MA. Azidothymidine (AZT) tolerance in patients with acquired immunodeficiency syndrome post Pneumocystis carinii pneumonia [abstract no. 387]. In: Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1987.
14. Steinberg J, Spear J, Murphy R, Kessler H, Pottage J, Benson C, Landay A, Phair J. Predictors of outcome on azidothymidine (AZT) [abstract no. 388]. In: Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1987.
15. Gill PS, Rarick M, Brynes RK, Causey D, Loureiro C, Levine AM. Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1987;107:502-5.
16. Spicehandler D, Dehovitz J, Gagliardi A, Grossman H, Markowitz M, Ristau P. An experience with zidovudine (AZT) in AIDS [abstract no. 385]. In: Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1987.
17. Cohn J, Shapiro C, Keyes C, Smothers K. Neurologic disease associated with zidovudine [abstract no. 381]. In: Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1987.
18. Yarchoan R, Berg G, Brouwers P, Fischl MA, Spitzer AR, Wichman A, Grafman J, Thomas RV, Safai B, Brunetti A, Perno CF, Schmidt PJ, Larson SM, Myers CE, Broder S. Response of human-immunodeficiency-virus-associated neurological disease to 3’-azido-3’-deoxythymidine. Lancet 1987;1:132-5.
19. Gottlieb MS, Wolfe PR, Chafey S. Case report: Response of AIDS-related thrombocytopenia to intravenous and oral azidothymidine (3’-azido-3’-deoxythymidine). AIDS Research and Human Retroviruses 1987;3:109-14.
20. Duvic M, Rios A, Brewton GW. Remission of AIDS-associated psoriasis with zidovudine. Lancet 1987;2:627.
21. Bach MC. Zidovudine for lymphocytic interstitial pneumonia associated with AIDS. Lancet 1987;2:796.
22. Hartshorn KL, Vogt MW, Chou T-C, Blumberg RS, Byington R, Schooley RT, Hirsch MS. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother 1987;31:168-72.
23. Mitsuya H, Mataukura M, Broder S. Rapid in vitro systems for assessing activity of agents against HTLV-III/LAV. In: Broder S, ed. AIDS: Modern concepts and therapeutic challenges. New York: Marcel Decker, 1987:303-33.
24. Mitchell WM, Montefiori DC, Robinson WE Jr, Strayer DR, Carter WA. Mismatched double-stranded RNA (ampligen) reduces concentration of zidovudine (azidothymidine) required for in-vitro inhibition of human immunodeficiency virus. Lancet 1987;1:890-2.
25. Hammer SM, Gillis JM. Synergistic activity of granulocyte-macrophage colony-stimulating factor and 3’-azido-3’-deoxythymidine against human immunodeficiency virus in vitro. Antimicrob Agents Chemother 1987;31:1046-50.
26. Vogt MW, Hartshorn KL, Furman PA, Chou T-C, Fyfe JA, Coleman LA, Crumpacker C, Schooley RT, Hirsch MS. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987;235:1376-9.
27. Baba M, Pauwels R, Balzarini J, Herdewijn P, De Clercq E, Desmyter J. Ribavirin antagonizes inhibitory effects of pyrimidine 2’,3’-dideoxynucleosides but enhances inhibitory effects of purine 2’,3’-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother 1987;31:1613-7.
28. Vogt MW, Hirsch MS. Treatment of human immunodeficiency virus infection. Infectious Disease Clinics of North America 1987;1:323-39.